FDA label 329d1081-3da6-4444-ab4c-6aa1c132c417

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
ce7d1f45-0e38-48c5-abf6-b229c6b2e9b3
SPL ID
329d1081-3da6-4444-ab4c-6aa1c132c417
Version
14
Effective date
2025-12-08
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:21:23

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 2 matching rows.

boxed warning

WARNING USE OF THIS PRODUCT WITHOUT DIRECT SUPERVISION OF A PHYSICIAN IS DANGEROUS ; Some patients afflicted with pernicious anemia may or not respond to the orally ingested vitamin B 12 , and there is no known way to predict which patients may respond and which patients may cease to respond; Periodic examinations and laboratory studies of pernicious anemia patients are essential and recommended ; and - The parenteral administration of ( cyano )cobalamin - or vitamin B 12 , is generally recognized as a fully effective treatment of pernicious anemia. Parenteral alkyl -cobalamin preparations have not been and are not authorized for use except by or on the prescription of a physician.

boxed warning table

<table width="100%"><tbody><tr styleCode="First Last"><td><content styleCode="bold">USE OF THIS PRODUCT WITHOUT DIRECT SUPERVISION OF A PHYSICIAN IS DANGEROUS</content>; Some patients afflicted with pernicious anemia may or not respond to the orally ingested vitamin B<sub>12</sub>, and there is no known way to predict which patients may respond and which patients may cease to respond; <content styleCode="bold">Periodic examinations and laboratory studies of pernicious anemia patients are essential and recommended</content>; and - The parenteral administration of (<content styleCode="italics">cyano</content>)cobalamin - or vitamin B<sub>12</sub>, is generally recognized as a fully effective treatment of pernicious anemia. Parenteral <content styleCode="italics">alkyl</content>-cobalamin preparations have not been and are not authorized for use except by or on the prescription of a physician.</td></tr></tbody></table>

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS Mild transient diarrhea, polycythemia vera, itching, transitory exanthema, feeling of swelling of entire body may occur with administration of cobalamin. Allergic sensitization has been reported following both oral and parenteral administration of folate. Sensitivity to porcine intrinsic factor derived from liver substance has been reported in patients, and may occur at any time; Biopar TM delta -FORTE contains a non-inhibitory form of intrinsic factor that is not derived from liver substance but rather just the mucosa (stomach substance) - in which such senstitivity is less likely to occur, however caution is advised and continuous monitoring under licensed medical supervision is required.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.